about
Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034A new PAMPA model proposed on the basis of a synthetic phospholipid membraneThe interaction of lipophilic drugs with intestinal fatty acid-binding protein.Selective κ opioid antagonists nor-BNI, GNTI and JDTic have low affinities for non-opioid receptors and transporters.In vitro cerebrovascular modeling in the 21st century: current and prospective technologies.Assessment of poly(methacrylic acid-co-N-vinyl pyrrolidone) as a carrier for the oral delivery of therapeutic proteins using Caco-2 and HT29-MTX cell lines.Intracellular accumulation of Praziquantel in T lymphoblastoid cell lines, CEM (parental) and CEMVBL(P-gp-overexpressing).Strategies to improve oral drug bioavailability.Drug-transporter mediated interactions between anthelminthic and antiretroviral drugs across the Caco-2 cell monolayers.Current industrial practices of assessing permeability and P-glycoprotein interactionCaco-2 cell permeability assays to measure drug absorption.Predictive models for oral drug absorption: from in silico methods to integrated dynamical models.Validation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis.Application of method suitability for drug permeability classification.Pros and cons of methods used for the prediction of oral drug absorption.Metabolites of Lactobacillus plantarum 2142 prevent oxidative stress-induced overexpression of proinflammatory cytokines in IPEC-J2 cell line.P-gp inhibition potential in cell-based models: which "calculation" method is the most accurate?Optimization of the Ussing chamber setup with excised rat intestinal segments for dissolution/permeation experiments of poorly soluble drugs.In vitro prediction of human intestinal absorption and blood-brain barrier partitioning: development of a lipid analog for micellar liquid chromatography.Orthogonal chromatographic descriptors for modelling Caco-2 drug permeability.Linking solubility and permeability assays for maximum throughput and reproducibility.In vitro M-like cells genesis through a tissue-engineered triple-culture intestinal model.
P2860
Q27489828-06BB2EF9-BF2E-45E7-973F-2B129E21493DQ28543187-57D48EA6-E526-445D-9133-F168CCC6B700Q30983194-9701E175-35FA-4035-B121-BF9A32AEDA53Q34366661-3C2C5079-BA5C-4C1B-8594-5752A94757B8Q34476565-22294035-2C57-4625-A1CE-AB87531EB854Q34588359-CCE5871E-E893-4F4C-8A79-207A26E45DF8Q36103626-B7FEA6FC-28C4-47A4-8DEC-89A36F566B83Q36316751-B2DB17B3-A6B5-463A-8796-0C209011C898Q36362462-550762F9-2969-4B0A-A370-54586415C000Q36439145-05CBFB81-1D2A-47AC-BCDA-BB9A27F4BF6CQ36572562-C5383143-3FCE-43FC-87DC-D01E7392720AQ36909311-0F0BC490-A008-40CA-BF2F-3067AC4C9200Q37643702-8A03B414-2FCD-41CB-8519-DB00EAC70F10Q37784730-2A80B2B3-ABB5-404E-A372-78E154E319CCQ38177366-69EC099E-C799-4C0C-BF64-C1B7FC96D9A2Q39369182-1BEA76CE-EE6D-414E-BD19-CC22070EF9ABQ39905120-2342AE94-75EF-45BC-A987-986F484CE5E9Q40529680-6304116B-A074-4351-87D9-50C2076F6047Q40639437-D6BF479B-4F74-4346-8204-1C4EF6AA327AQ45865440-BFF0EACA-2B1A-4C43-A4FE-0E21D63EA42AQ48847422-1908A6A1-51CC-4E0D-8046-9FD122E16C1AQ51793501-8B417820-5519-432D-9467-3F0EB738798F
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Assessing the absorption of new pharmaceuticals.
@ast
Assessing the absorption of new pharmaceuticals.
@en
Assessing the absorption of new pharmaceuticals.
@nl
type
label
Assessing the absorption of new pharmaceuticals.
@ast
Assessing the absorption of new pharmaceuticals.
@en
Assessing the absorption of new pharmaceuticals.
@nl
prefLabel
Assessing the absorption of new pharmaceuticals.
@ast
Assessing the absorption of new pharmaceuticals.
@en
Assessing the absorption of new pharmaceuticals.
@nl
P356
P1476
Assessing the absorption of new pharmaceuticals.
@en
P2093
Hidalgo IJ
P304
P356
10.2174/1568026013395010
P577
2001-11-01T00:00:00Z